News
NRSN
1.690
-3.98%
-0.070
NeuroSense Therapeutics Consensus Price Target Increased by 15.35% to $113.39
NASDAQ · 6d ago
Weekly Report: what happened at NRSN last week (1102-1106)?
Weekly Report · 11/09 09:48
NeuroSense Adds New Data To PrimeC Application, Delays Health Canada Filing To March 2027
Benzinga · 11/02 18:51
NeuroSense Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones · 11/02 17:41
HC Wainwright & Co. Downgrades NeuroSense Therapeutics to Neutral
Benzinga · 11/02 17:32
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 11/02 17:05
NeuroSense downgraded to Neutral from Buy at H.C. Wainwright
TipRanks · 11/02 16:45
NeuroSense downgraded at H.C. Wainwright on extended PrimeC timelines
TipRanks · 11/02 16:45
NeuroSense adds new data to its Canadian submission of ALS candidate
TipRanks · 11/02 14:16
Weekly Report: what happened at NRSN last week (1026-1030)?
Weekly Report · 11/02 09:48
NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026
PR Newswire · 10/29 15:30
NeuroSense Therapeutics Moves to Early PrimeC Commercialization in U.S.
TipRanks · 10/26 17:17
NeuroSense Therapeutics Ltd. Targets Revenues in 2027 Under Strategic Collaboration Agreement
NASDAQ · 10/26 16:58
Neurosense Therapeutics Inks Collaboration Agreement To Advance Supply Of PrimeC To Treat Amyotrophic Lateral Sclerosis
Benzinga · 10/26 16:51
Weekly Report: what happened at NRSN last week (1019-1023)?
Weekly Report · 10/26 09:48
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/19 17:05
NeuroSense Files U.S. Patent to Extend PrimeC into Traumatic Brain Injury
TipRanks · 10/19 14:23
NeuroSense files patent in USPTO covering methods to treat TBI
TipRanks · 10/19 12:37
NeuroSense Therapeutics Files U.S. Patent Application Covering Methods Of Treating Traumatic Brain Injury And Related Central Nervous System Injuries With Combination Of Ciprofloxacin And Celecoxib
Benzinga · 10/19 12:28
Weekly Report: what happened at NRSN last week (1012-1016)?
Weekly Report · 10/19 09:48
More
Webull provides a variety of real-time NRSN stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSN
NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage pharmaceutical company engaged in the development of therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is an oral fixed-dose combination therapy designed for the treatment of ALS. In addition to PrimeC, the Company conducts research and development activities focused on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease. The Company develops pharmaceutical products and therapeutic solutions aimed at addressing unmet medical needs in neurological diseases and related central nervous system disorders. The Company also advances therapies for rare neurological conditions.